Status:
RECRUITING
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Refractory or Relapsed Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cel...
Detailed Description
In this study the search for relevant radiomic signature will be carried out for each patient benefiting from an 18FDG PET-CT during the pre-treatment assessment and then in the follow-up at 1 month, ...
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years old
- Patients with histologically proven, refractory or relapsed, non-Hodgkin's lymphoma as indicated for CAR T-cell therapy
- ECOG score 0 to 2
- Affiliated patient or beneficiary of a social security scheme
- Patient having signed prior informed consent.
Exclusion
- Be under 18 years old,
- Contraindication to performing 18FDG PET-CT examinations: severe claustrophobia, unbalanced diabetes during PET-CT examinations (young capillary blood sugar ≥ 11 mmol),
- Any participation in other biomedical studies relating to drugs, medical devices or imaging techniques is prohibited, with the exception of so-called non-health product biomedical studies.
- Hypersensitivity to the active substance or to any of the excipients in the composition of CAR T-cells preparations
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
August 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05422521
Start Date
August 29 2022
End Date
February 28 2026
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, France, 06000